Sai Life Sciences Limited has announced a strategic collaboration with Mabtech, a global life science tools company. This partnership establishes Sai's Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA™ platform. Under this agreement, both companies will jointly offer advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, utilizing the EYRA platform installed at Sai's Boston discovery site. This initiative aims to accelerate access to next-generation immune profiling capabilities for biopharmaceutical and biotechnology firms engaged in immuno-oncology, vaccines, inflammation, and cellular therapy. The collaboration includes joint service delivery of EYRA-based immunology panels and custom assays, co-branded demonstrations, shared thought leadership, and integrated business development engagement. This strategic move is expected to enhance Sai Life Sciences' ability to support complex immunology programs and help clients expedite the transition from biological hypotheses to confident development decisions.
